Immunovant Stock Options Expiring on 20th of December

IMVT Stock  USD 28.20  0.53  1.84%   

Immunovant Total Stockholder Equity

Total Stockholder Equity

648.64 Million

At this time, Immunovant's Total Stockholder Equity is comparatively stable compared to the past year.

Immunovant Corporate Management

Jay StoutChief OfficerProfile
Mark LevineChief SecretaryProfile
Lauren MBAVice MarketingProfile
Eva MBAChief OfficerProfile
Julie KirschlingSenior ManagementProfile
Christine BlodgettSenior ResourcesProfile
MBA MDEx BoardProfile

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.